Disc Medicine Inc
IRONHealthcare|Biotechnology|USA
$76.59
-2.32 (-2.94%)
Tangible Book
$18.03
Earnings Power
$18.04
Clinical Trials (11)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06910358 Study of Bitopertin in Participants With EPP or XLP (APOLLO) | Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP) | P3 | Active | 183 | RCT, Double-blind | Placebo, DISC-1459 |
| NCT07368972 Study of DISC-0974-201 in Participants With IBD and Anemia | Inflammatory Bowel Disease (IBD), Anemia | P2 | Recruiting | 21 | RCT, Double-blind | DISC-0974, Placebo |
| NCT05320198 Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia | Myelofibrosis; Anemia, Anemia | P1P2 | Recruiting | 150 | RCT, Open-label | DISC-0974 |
| NCT06985147 A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV) | Polycythemia Vera (PV) | P2 | Recruiting | 60 | Open-label | DISC-3405 |
| NCT07187973 A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) | Sickle Cell Disease | P1 | Recruiting | 24 | Open-label | DISC-3405 |
| NCT05883748 HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP | Erythropoietic Protoporphyria | P2P3 | By Invite | 230 | RCT, Open-label | DISC-1459, DISC-1459 |
| NCT05308472 Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP | Erythropoietic Protoporphyria | P2 | Completed | 75 | RCT, Double-blind | DISC-1459, DISC-1459, Placebo |
| NCT04999527 Study to Evaluate the Safety, Tolerability, PK and PD of DISC-0974 in Healthy Subjects | Healthy Volunteer | P1 | Completed | 42 | RCT, Double-blind | DISC-0974, Placebo |
| NCT06050915 A Study of DISC-3405 in Healthy Volunteers | Healthy Volunteer | P1 | Completed | 64 | RCT, Double-blind | DISC-3405, DISC-3405, Placebo, Placebo |
| NCT05745883 Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia | Chronic Kidney Diseases, Anemia of Chronic Kidney Disease | P1 | Completed | 55 | RCT, Double-blind | DISC-0974, Placebo |
| NCT07603401 Expanded Access Program of Bitopertin For Participants With EPP or XLP | Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP) | AVAILABLE | — | — | DISC-1459 |